We are planning a nested case-control study to examine how the use of angiotensin-converting enzyme inhibitors, statins and non-steroidal anti-inflammatory drugs influences the risk of progression from Barrett’s oesophagus to oesophageal adenocarcinoma. Here, ACE is linked to esophageal adenocarcinoma.